Autologous Stem Cell Transplantation for Adult Acute Myelocytic Leukemia in First Remission-Better Outcomes After Busulfan and Melphalan Compared With Busulfan and Cyclophosphamide: A Retrospective Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Basit Öğe Kaydı
dc.contributor.authorGorin, Norbert-Claude
dc.contributor.authorLabopin, Myriam
dc.contributor.authorCzerw, Tomasz
dc.contributor.authorPabst, Thomas
dc.contributor.authorBlaise, Didier
dc.contributor.authorDumas, Pierre-Yves
dc.contributor.authorNemet, Damir
dc.contributor.authorArcese, William
dc.contributor.authorTrisolini, Silvia Maria
dc.contributor.authorWu, Depei
dc.contributor.authorHuynh, Anne
dc.contributor.authorZuckerman, Tsila
dc.contributor.authorMeijer, Ellen
dc.contributor.authorCagirgan, Seckin
dc.contributor.authorCornelissen, Jan
dc.contributor.authorHouhou, Mohamed
dc.contributor.authorPolge, Emmanuelle
dc.contributor.authorMohty, Mohamad
dc.contributor.authorNagler, Arnon
dc.date.accessioned2019-10-27T11:10:03Z
dc.date.available2019-10-27T11:10:03Z
dc.date.issued2017
dc.departmentEge Üniversitesien_US
dc.description57th Annual Meeting and Exposition of the American-Society-of-Hematology -- DEC 04-08, 2015 -- Orlando, FLen_US
dc.description.abstractBACKGROUND: Autologous stem cell transplantation (ASCT) for adult acute myelogenous leukemia (AML) is a valid therapeutic option for patients with good-risk and intermediate-risk disease. The authors used the registry of the European Society for Blood and Marrow Transplantation to compare combined busulfan and melphalan (BUMEL) with combined busulfan and cyclophosphamide (BUCY) before transplantation. METHODS: From 2005 to 2013, 853 patients with available cytogenetics underwent ASCT in first remission, including 257 after receiving BUMEL and 596 after receiving BUCY. The proportion of patients with good-risk AML was lower in those who received BUMEL (14% vs 20%; P = .02). More patients who received BUMEL underwent autograft in molecular remission (89% vs 78%; P = .02). Three years after transplantation, the relapse incidence (RI) was 48.7%, the leukemia-free survival (LFS) rate was 47.7%, the overall survival (OS) rate was 66.2%, and the nonrelapse mortality (NRM) rate was 3.6%. RESULTS: Patients who underwent an autograft after receiving BUMEL fared better than those who underwent an autograft after receiving BUCY with a lower RI (39.5% vs 52.2%; hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.49-0.87; P = .003) a better LFS (55.4% vs 44.6%; HR, 0.69; 95% CI, 0.53-0.89; P = .005), and a better OS (73.8% vs 63%; HR, 0.62; 95% CI, 0.47-0.82; P = .0007). There was no difference in the NRM rate (BUMEL vs BUCY, 4.5% vs 3.2%, respectively). Among 74 patients in the BUMEL group and 187 in the BUCY group who underwent autograft in molecular remission, the RI was 30% versus 51%, respectively (univariate analysis; P = .01), and the LFS rate was 66% versus 47%, respectively (univariate analysis; P = .03). CONCLUSIONS: In patients with AML in first complete remission who undergo ASCT, the BUMEL combination is a better preparative regimen. (C) 2016 American Cancer Society.en_US
dc.description.sponsorshipAmer Soc Hematolen_US
dc.identifier.doi10.1002/cncr.30400en_US
dc.identifier.endpage831en_US
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.issue5en_US
dc.identifier.pmid27906458en_US
dc.identifier.startpage824en_US
dc.identifier.urihttps://doi.org/10.1002/cncr.30400
dc.identifier.urihttps://hdl.handle.net/11454/32353
dc.identifier.volume123en_US
dc.identifier.wosWOS:000396842400015en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofCanceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectacute myelogenous leukemiaen_US
dc.subjectautologous stem cell transplantationen_US
dc.subjectbusulfan and melphalanen_US
dc.subjectmolecular remissionen_US
dc.subjectpretransplantation regimenen_US
dc.titleAutologous Stem Cell Transplantation for Adult Acute Myelocytic Leukemia in First Remission-Better Outcomes After Busulfan and Melphalan Compared With Busulfan and Cyclophosphamide: A Retrospective Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu